Display options
Cite
Ravegnini G, Ricci R. Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?. Epigenet Insights. 2019;12:2516865719842534doi: 10.1177/2516865719842534.
Ravegnini, G., & Ricci, R. (2019). Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?. Epigenetics insights, 122516865719842534. https://doi.org/10.1177/2516865719842534
Ravegnini, Gloria, and Ricci, Riccardo. "Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?." Epigenetics insights vol. 12 (2019): 2516865719842534. doi: https://doi.org/10.1177/2516865719842534
Ravegnini G, Ricci R. Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?. Epigenet Insights. 2019 Apr 12;12:2516865719842534. doi: 10.1177/2516865719842534. eCollection 2019. PMID: 31020269; PMCID: PMC6463228.
Copy Download .nbib Format: NLM
Share it on

Epigenet Insights. 2019 Apr 12;12:2516865719842534. doi: 10.1177/2516865719842534. eCollection 2019.

Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?.

Epigenetics insights

Gloria Ravegnini, Riccardo Ricci

Affiliations

  1. Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
  2. Department of Pathology, Università Cattolica del Sacro Cuore, Rome, Italy.
  3. UOC di Anatomia Patologica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

PMID: 31020269 PMCID: PMC6463228 DOI: 10.1177/2516865719842534

Abstract

Various molecular triggers define heterogeneous subsets of gastrointestinal stromal tumors (GISTs), differing in clinical behavior and drug sensitivity.

Keywords: DNA methylation; O6-methylguanine-DNA methyltransferase; alkylating agents; gastrointestinal stromal tumor; molecular diagnosis; wild-type gastrointestinal stromal tumor

Conflict of interest statement

Declaration of conflicting interests:R.R. received speaker’s honoraria from Novartis. G.R. declares no conflicts of interest.

References

  1. N Engl J Med. 2000 Nov 9;343(19):1350-4 - PubMed
  2. N Engl J Med. 2001 Apr 5;344(14):1052-6 - PubMed
  3. Cancer. 2003 Dec 15;98(12):2693-9 - PubMed
  4. J Gastrointest Surg. 2003 Dec;7(8):1004-14; discussion 1014 - PubMed
  5. Cancer. 2005 Oct 15;104(8):1706-12 - PubMed
  6. Cancer Chemother Pharmacol. 2006 Nov;58(5):634-9 - PubMed
  7. J Clin Oncol. 2007 May 1;25(13):1760-4 - PubMed
  8. N Engl J Med. 2007 Sep 6;357(10):1054-6 - PubMed
  9. Cancer Sci. 2008 Feb;99(2):253-9 - PubMed
  10. Biologics. 2010 Feb 04;4:19-31 - PubMed
  11. Gut. 2012 Mar;61(3):392-401 - PubMed
  12. Mol Cancer Ther. 2011 Dec;10(12):2215-23 - PubMed
  13. Curr Oncol Rep. 2013 Aug;15(4):386-95 - PubMed
  14. Virchows Arch. 2013 Oct;463(4):481-7 - PubMed
  15. Br J Cancer. 2014 Mar 4;110(5):1155-62 - PubMed
  16. Nat Genet. 2014 Apr;46(4):364-70 - PubMed
  17. Ther Adv Med Oncol. 2014 May;6(3):115-27 - PubMed
  18. Int J Biochem Cell Biol. 2014 Aug;53:514-9 - PubMed
  19. Curr Treat Options Oncol. 2014 Sep;15(3):493-506 - PubMed
  20. Genet Med. 2015 May;17(5):391-5 - PubMed
  21. Nat Rev Cancer. 2014 Nov;14(11):747-53 - PubMed
  22. Clin Epigenetics. 2015 Dec 10;7:127 - PubMed
  23. JAMA Oncol. 2016 Jul 1;2(7):922-8 - PubMed
  24. Ann Oncol. 2016 Sep;27(9):1794-9 - PubMed
  25. Hered Cancer Clin Pract. 2016 Jul 19;14:15 - PubMed
  26. J Clin Oncol. 2017 Feb 10;35(5):523-528 - PubMed
  27. Cancer Treat Rev. 2017 Mar;54:10-23 - PubMed
  28. Pathologica. 2016 Sep;108(3):90-103 - PubMed
  29. J Transl Med. 2017 May 23;15(1):113 - PubMed
  30. Trends Cancer. 2018 Feb;4(2):110-118 - PubMed
  31. ESMO Open. 2018 Jun 28;3(4):e000390 - PubMed
  32. Recent Results Cancer Res. 2018;211:45-56 - PubMed
  33. Clin Epigenetics. 2019 Jan 7;11(1):2 - PubMed

Publication Types